How semaglutide's action in the body leads to weight loss

Step 1: a weekly injection that starts a hormone-level conversation

After a subcutaneous injection into the abdomen, thigh or upper arm, semaglutide enters the bloodstream and binds to GLP-1 receptors throughout the body. GLP-1 is a hormone your gut releases naturally after a meal, but it is broken down within minutes. Semaglutide is engineered to resist that breakdown, its molecular structure includes a fatty-acid chain that tethers it to albumin in the blood, extending its working life to around a week. That is why a single weekly dose is enough to keep the receptors engaged continuously. The semaglutide overview on our treatment pages explains the licensed UK options in more detail. One practical point: the timing of your weekly injection is flexible, but keeping it consistent (same day each week) helps maintain steady levels. Plenty of people choose Sunday evening, or the day after payday, or whichever day fits their routine; it genuinely does not need to be clinically precise.

Step 2: signals reach the brain before they reach the stomach

The brain effects are arguably the most significant part of semaglutide's action, and they often surprise people. Receptors in the hypothalamus (the region that regulates hunger and satiety) respond to semaglutide by reducing appetite signals. People on treatment commonly describe a quietening of food-related thoughts, a reduced urge to eat between meals, and smaller portions feeling satisfying. This is not willpower; it is receptor-level biology. Semaglutide also acts on reward pathways, which may reduce the pull of highly palatable foods specifically. You can read a more detailed look at how semaglutide works at a molecular level in our semaglutide mechanism of action page. The NHS patient-level information on semaglutide, available at nhs.uk/medicines/semaglutide, covers how the medicine works alongside its side-effect profile in plain language.

Step 3: slower gastric emptying changes the meal experience

In the gut, semaglutide slows the rate at which the stomach empties its contents into the small intestine. The practical effect is that food stays in the stomach longer, which prolongs the physical feeling of fullness after eating. It also moderates the post-meal spike in blood glucose, relevant for people with type 2 diabetes or prediabetes, and part of why GLP-1 medicines were first developed for blood-sugar management before their weight-loss potential became clear. The appetite and gastric effects work together rather than independently. Reduced hunger means you eat less; slower emptying means you feel full sooner and for longer on what you do eat; the brain reward changes reduce hedonic snacking on top of that. It is worth understanding when semaglutide's effects typically begin, since the first weeks of treatment are often at the low starter dose and the appetite changes build gradually as the dose is titrated upward by your prescriber.

Step 4: what the trial evidence shows, and the clinical context around it

The STEP 1 trial (a 68-week randomised study in adults with obesity but without type 2 diabetes) found an average body-weight reduction of around 15% at the 2.4mg weekly maintenance dose of semaglutide, compared with around 2.4% with placebo, alongside lifestyle support. The full STEP 1 paper is published in the New England Journal of Medicine for anyone who wants to read the primary data. Those are population averages from a controlled trial; individual results vary, and clinical trials run under conditions that differ from everyday life. NICE recommends semaglutide for weight management under specific eligibility criteria, set out in NICE technology appraisal TA875. If you are considering the cost of Wegovy as a private treatment, our page covering how Wegovy works in practice gives useful context alongside the clinical picture. The mechanism described here is the same whether treatment reaches you through an NHS specialist service or a regulated private pharmacy. What changes is the access route, the eligibility threshold, and the clinical team reviewing you. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician) on the day it is submitted. If semaglutide is clinically suitable for you, check your eligibility and start a free consultation.